Multicomponent Antioxidant Composition for Alzheimer's Oxidative Stress
Solution Overview
Problem
Current treatments for Alzheimer's disease and senile dementia fail to effectively address oxidative stress at the cerebral level, leading to ongoing progression of the disease due to unmanaged blood-brain barrier dysfunction, amyloid deposition, and mitochondrial dysfunction.
Innovation Solution
A pharmaceutical composition comprising carnosine, thiamine, riboflavin, nicotinamide, pyridoxine, folic acid, cyanocobalamin, vitamin C, vitamin E, coenzyme Q10, β-carotene, selenium, L-cysteine, and Ginkgo biloba extract, which targets key elements of cerebral oxidative stress, including erythrocytes, to restore normal erythrocyte function and improve blood circulation in the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Alzheimer's disease, then general symptom management is provided, but oxidative stress at the cerebral level is not effectively addressed, leading to ongoing disease progression
Solution Approach 1:
The treatment is divided into multiple components targeting different aspects of oxidative stress: direct antioxidants (vitamins C and E) for immediate neutralization of free radicals, indirect antioxidants (carnosine, coenzyme Q10, selenium) for enzymatic antioxidant systems, and B vitamins for homocysteine metabolism. This segmented approach addresses multiple pathways of oxidative damage simultaneously, resolving the contradiction between general symptom management and specific oxidative stress treatment.
Solution Approach 2:
The invention uses a composite formulation combining 15 different substances with complementary mechanisms of action. This composite approach creates a synergistic effect where direct and indirect antioxidants work together, B vitamins support metabolic pathways, and Ginkgo biloba provides additional cerebral protection. The composite formulation effectively addresses oxidative stress that single agents cannot manage alone.
2Reliability
If blood-brain barrier dysfunction and amyloid deposition are present, then cerebral oxidative stress occurs, but current treatments fail to restore normal erythrocyte function and improve blood circulation
Solution Approach 1:
The formulation targets specific biochemical parameters: B vitamins (B6, B9, B12) modify homocysteine levels to reduce erythrocyte oxidation, vitamin E and carnosine change the oxidation state of erythrocyte membranes, and coenzyme Q10 alters mitochondrial function in erythrocytes. These parameter changes restore erythrocyte deformability and circulation capacity without requiring structural modifications to the blood-brain barrier or removal of amyloid deposits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly reduces fusiform erythrocytes, enhances antioxidant defenses, and improves oxygen delivery to the brain, thereby slowing disease progression and improving cognitive functions in patients with Alzheimer's disease.
Implementation Method 1
an OS (oxidative stress) condition has long been observed, determinable by common indices of stress in plasma, as well as in cerebrospinal fluid (CSF) and post-mortem analyzed cerebral tissue
Implementation Method 2
The composition significantly reduces fusiform erythrocytes, enhances antioxidant defenses, and improves oxygen delivery to the brain
Data Source
AI summary
The present invention relates to pharmaceutical compositions active in preventing, stabilizing and treating Alzheimer's disease and cognitive dysfunctions related thereto.
